Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.77 extracted from

  • Choueiri, T.K.; Xie, W.; DAmico, A.V.; Ross, R.W.; Hu, J.C.; Pomerantz, M.; Regan, M.M.; Taplin, M.E.; Kantoff, P.W.; Sartor, O.; Oh, W.K.
    Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy (2009), Cancer, 115, 981-987.
    View publication on PubMedView publication on EuropePMC
Search for more literature for 3.4.21.77

Application

Application Comment Organism
medicine PSA kinetics at the initiation of androgen-deprivation therapy can predict overall survival in patients with metastatic hormone-sensitive prostate cancer Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
serum
-
 Homo sapiens
-

Synonyms

Synonyms Comment Organism
prostate-specific antigen
-
 Homo sapiens
PSA
-
 Homo sapiens

General Information

General Information Comment Organism
physiological function a faster time to reach a PSA nadir after the initiation of androgen-deprivation therapy is associated with shorter survival duration in men with metastatic hormone-sensitive prostate cancer. Association between time to PSA nadir and survival is limited only to patients who have a PSA nadir more than 0.2 ng/ml Homo sapiens